诺泰生物(688076) - 2024 Q3 - 季度业绩预告

Financial Performance Forecast - For Q3 2024, the company expects a net profit attributable to shareholders of between 100 million and 140 million yuan, representing an increase of 50.14 million to 90.14 million yuan, or a year-on-year growth of 100.56% to 180.78%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is also projected to be between 100 million and 140 million yuan, reflecting an increase of 54.65 million to 94.65 million yuan, or a year-on-year growth of 120.49% to 208.69%[3] - In Q3 2023, the company's total profit was 66.97 million yuan, with a net profit attributable to shareholders of 49.86 million yuan and a net profit after deducting non-recurring gains and losses of 45.35 million yuan[4] Factors Influencing Performance - The significant increase in performance is primarily attributed to substantial growth in sales revenue from peptide raw materials compared to the previous year[5] - There are uncertainties regarding the recognition of revenue for some orders due to factors such as shipping and logistics[6] Preliminary Data and Audit Status - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by registered accountants[6] - Investors are advised that the forecast data is preliminary and the accurate financial data will be disclosed in the official Q3 2024 report[7]